Recombinant high-density lipoprotein formulations

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Pharmacology

Background:

• High-density lipoprotein cholesterol (HDL-C) is a biomarker for residual cardiovascular disease (CVD) risk in patients on low-density lipoprotein cholesterol (LDL-C) lowering therapies.
• Limited evidence exists for increasing low HDL-C levels, with confounding metabolic interactions between very low-density lipoprotein (VLDL) and LDL particles.
• Despite limitations, novel strategies targeting HDL are of significant interest.

Purpose of the Study:

• To review current knowledge on novel recombinant HDL therapies.
• To discuss the future prospects of these therapies in mitigating atherosclerotic CVD events.

Main Methods:

• Investigation of recombinant HDL formulations, including apolipoprotein A-1 (apoA-1)-bound phospholipid disks, delipidated HDL particles, mutant apoA-1 proteins, and apoA-1 mimetic peptides.
• Review of data from animal studies and some human trials.
• Analysis of the potential of these therapies in clinical trials for atherosclerosis and CVD events.

Main Results:

• Recombinant HDL formulations mimic the pre-beta fraction of native HDL, facilitating cholesterol efflux from macrophages.
• Various formulations have been explored in preclinical and early clinical settings.
• Further evaluation in large-scale clinical trials is necessary to establish efficacy in preventing CVD events.

Conclusions:

• Novel recombinant HDL therapies represent a promising avenue for managing residual CVD risk.
• These therapies aim to enhance cholesterol efflux and reduce atherosclerotic burden.
• Clinical trials are essential to validate the therapeutic potential of recombinant HDL in preventing cardiovascular events.